Hepatitis, Viral, Human Clinical Trial
Official title:
A Multiple Dose Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of MK-8742 in Hepatitis C Infected Males
The purpose of this study is to assess the safety, pharmacokinetics (PK) and pharmacodynamics
of elbasvir (MK-8742) in Hepatitis C Virus (HCV)-infected participants. There will be 3 parts
to this study; Part I will enroll only genotype (GT) 1 HCV-infected participants, Part II
will enroll GT3 HCV-infected participants, and Part III will enroll only GT1a HCV-infected
participants. All parts may run concurrently, or Parts II and III may be staggered.
Hypothesis (Part I): At a once-daily dose that is sufficiently safe and well tolerated in
HCV-infected participants, elbasvir administered for 5 consecutive days has superior
antiviral activity in GT1 HCV-infected participants compared to placebo, as measured by
change from baseline in plasma HCV ribonucleic acid (RNA; log 10 copies/mL) at Day 5, 24-hour
postdose timepoint. (a true mean viral RNA reduction of at least 3 log10 is anticipated).
Hypothesis (Part II): At a dose that is sufficiently safe in GT3 HCV-infected participants,
the mean maximum reduction in HCV viral load is greater following multiple dose oral
administration of elbasvir as compared to placebo.
Hypothesis (Part III): At a once-daily dose that is sufficiently safe and well tolerated in
HCV-infected participants, elbasvir administered for 5 consecutive days has superior
antiviral activity in GT1a HCV-infected participants compared to placebo, as measured by
change from baseline in plasma HCV RNA (log 10 copies/mL) at Day 5, 24-hour postdose
timepoint. (a true mean viral RNA reduction of at least 3 log10 is anticipated).
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00342186 -
Genes Involved in Resistance or Susceptibility to Hepatitis B Virus
|
||
| Completed |
NCT00097006 -
Retrovirus Epidemiology Donor Study-II (REDS-II)
|
N/A | |
| Completed |
NCT00007371 -
Hepatitis C in Clinically Discordant Hemophilic Siblings
|
N/A | |
| Completed |
NCT00005305 -
Hepatitis Delta Infections in Hemophiliacs
|
N/A | |
| Completed |
NCT00005304 -
Delta Hepatitis and Liver Disease in Hemophiliacs
|
||
| Completed |
NCT00000583 -
Hepatitis B Vaccine Clinical Trial
|
Phase 3 | |
| Completed |
NCT00000580 -
Interruption of Maternal-to-Infant Transmission of Hepatitis B by Means of Hepatitis B Immune Globulin
|
Phase 3 | |
| Recruiting |
NCT03776760 -
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
|
||
| Terminated |
NCT00318682 -
Evaluation and Medico-Economic Study of FIBROSCAN in Patients With Viral Hepatitis
|
N/A | |
| Completed |
NCT00915057 -
Effect of Chronic Viral Hepatitis on the Pharmacokinetics of NRL972.
|
Phase 2 | |
| Completed |
NCT00564811 -
Effect of Agaricus Blazei (Murrill) ss. Heinemann (Sun Mushroom)
|
N/A | |
| Completed |
NCT00005306 -
Natural History of Post-transfusion Non-A, Non-B Hepatitis
|
N/A | |
| Completed |
NCT01804829 -
Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.
|
Phase 3 | |
| Completed |
NCT01170741 -
Computer-Assisted Tailored Cue-card Health [CATCH] Study
|
Phase 1 | |
| Completed |
NCT01163240 -
Epidemiological Study in Children and Adolescents With Chronic Hepatitis B
|
N/A | |
| Completed |
NCT00116454 -
Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis
|
Phase 3 | |
| Completed |
NCT00005309 -
Prospective Study of HIV Infection in Hemophiliacs
|
||
| Completed |
NCT00913757 -
A Study of Molecular and Genetic Factors for Liver Cancer in the Greater Baltimore Area
|
||
| Completed |
NCT00608192 -
HIV and Hepatitis Care Coordination in Methadone Treatment
|
N/A | |
| Enrolling by invitation |
NCT05492565 -
Seville Cohort of People at Substantial Risk for HIV Infection on Pre-exposure Prophylaxis
|